The molecular epidemiology of lung cancer

Simon D. Spivack, Michael J. Fasco, Vernon E. Walker, Laurence S. Kaminsky

Research output: Contribution to journalReview article

83 Scopus citations

Abstract

One in ten tobacco smokers develops bronchogenic carcinoma over a lifetime. The study of susceptibility of an individual and a population to lung canter traditionally has been limited to the study of tobacco smoke dose and family history of cancer. New insights into lung carcinogenesis have made the study of molecular markers of risk possible in human populations in the emerging field of molecular epidemiology. This review summarizes data addressing the relationships of human lung cancer to polymorphisms of phase I procarcinogen-activating and phase II-deactivating enzymes and intermediate biomarkers of DNA mutation, such as DNA adducts, oncogene and tumor suppressor gene mutation, and polymorphisms. These parameters are reviewed as they relate to tobacco smoke exposure, procarcinogen metabolizing polymorphisms, and the presence of lung cancer. Problem areas in biomarker validation, such as cross-sectional data interpretation, tissue source, race, statistical power, and ethical implications are addressed.

Original languageEnglish (US)
Pages (from-to)319-365
Number of pages47
JournalCritical reviews in toxicology
Volume27
Issue number4
DOIs
Publication statusPublished - Jan 1 1997
Externally publishedYes

    Fingerprint

Keywords

  • Biomarkers
  • DNA adducts
  • Lung cancer
  • Oncogenes
  • Phase I metabolism
  • Phase II metabolism
  • Susceptibility
  • Tumor suppressor genes

ASJC Scopus subject areas

  • Toxicology

Cite this